Perioperative Application of Liraglutide for the Prevention of Postoperative Delirium among Elderly Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Single-Center Randomized Controlled Study

开始日期2024-04-30

申办/合作机构-

NCT06171152 / Not yet recruiting早期临床1期IIT

Examining the Utility of GLP-1 Agonists as Neuroprotective Agents Through a Pilot Clinical Trial in High Risk Population With Neurocognitive Deficits and Obesity

This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life.
By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a certain disease marker in the body called Brain Derived Neurotrophic Factor (BDNF). Participation in this research will last about 21 weeks.

开始日期2024-04-01

申办/合作机构

The University of Chicago

NCT06283641 / Enrolling by invitationN/A

Multicentre, Single-arm, Non-interventional Regulatory Post- Marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

This is a non-interventional study to evaluate the safety and effectiveness of Saxenda® in obese adults and adolescents in Taiwan. The participants will recieve Saxenda® treatment which is a medicine that doctors can already prescribe.
The study will last for about 26 weeks.

开始日期2024-02-23

申办/合作机构

Novo Nordisk A/S

100 项与利拉鲁肽相关的临床结果

登录后查看更多信息

100 项与利拉鲁肽相关的转化医学

登录后查看更多信息

100 项与利拉鲁肽相关的专利（医药）

登录后查看更多信息

3,745

项与利拉鲁肽相关的文献（医药）

2024-04-01·The American Journal of Emergency Medicine

GLP-1 agonists: A review for emergency clinicians

Review

作者: Koyfman, Alex ; Pelletier, Jessica ; Long, Brit ; Bridwell, Rachel E

INTRODUCTION:

Glucagon-like peptide 1 (GLP-1) based therapies, including GLP-1 agonists, are currently in use for treatment of diabetes and obesity. However, several complications may occur with their use.

OBJECTIVE:

This narrative review provides a focused evaluation of GLP-1 agonist therapy and associated complications for emergency clinicians.

DISCUSSION:

GLP-1 agonists potentiate insulin release and reduce gastric emptying and food intake. These agents have demonstrated significant improvements in glucose control in diabetics and weight loss in obese patients. The two most common agents include subcutaneous semaglutide (Ozempic, approved for type 2 diabetes, and Wegovy, approved for weight loss) and liraglutide (Saxenda, approved for weight loss, and Victoza, approved for type 2 diabetes), though an oral formulation of semaglutide is available (Rybelsus). While these drugs are associated with improved long-term outcomes, there are a variety of associated adverse events. The most common include gastrointestinal (GI) adverse events such as nausea, vomiting, diarrhea, and abdominal pain. Pancreatitis and biliary disease may also occur. Hypersensitivity including injection site reactions have been associated with use, with reports of anaphylaxis and other rashes. Renal adverse events are most commonly associated with severe GI losses. Hypoglycemia may occur when these agents are used with sulfonylureas or insulin. There is also an increased risk of diabetic retinopathy. Due to the current shortage and expense of these medications, many patients have attempted to obtain these medications from non-licensed and unregulated agents, which may be associated with increased risk of serious complications.

CONCLUSIONS:

An understanding of the indications for GLP-1 agonist use and associated adverse events can assist emergency clinicians.

2024-02-01·Clinical Obesity

Long‐term weight outcomes in patients treated with liraglutide 3.0 mg in real‐world clinical practice

Article

作者: le Roux, Carel ; Grannell, Andrew ; Al-Najim, Werd

Summary:

Long‐term weight outcomes reflect the success of obesity treatment. Weight regain during treatment for obesity is a biologically maladaptive response that can be considered a central feature of the disease. This phenomenon has been well documented in patients treated with lifestyle changes and bariatric surgery. In patients treated with liraglutide 3.0 mg this has been documented in randomized control trials, but real‐world analysis is lacking. The aim of this retrospective observational study was to explore the long‐term weight outcomes in patients treated with liraglutide 3.0 mg in a real‐world clinical practice. The association between body composition changes and weight outcomes was also explored. The study included 25 patients treated with multi‐modal care that included liraglutide 3.0 mg over a period of 78 weeks. Body composition was examined via dual x‐ray absorptiometry at 16 and 32 weeks, with body weight captured up until 78 weeks for all patients. Weight loss (R2 = 0.39, p < .001), fat mass loss (R2 = 0.32, p = .003) and fat‐free mass loss (R2 = 0.19, p = .03) were all associated with weight change from artificial nadir, which was, on average, 3.8 kg. For body composition, after adjustment, only fat mass loss was associated weight regain (R2 = 0.32, p = .01). In conclusion, in patients with clinical obesity treated with liraglutide 3.0 mg in a real‐world clinical setting, fat mass loss was associated with weight regain. Whilst weight regain occurred on average, the magnitude was less than that observed in patients treated with lifestyle alone and weight loss remained clinically significant for most patients.

2024-01-22·Expert Opinion on Pharmacotherapy

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Review

作者: Mondoh, Alvin ; Le Roux, Carel

INTRODUCTION:

Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.

AREAS COVERED:

Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.

EXPERT OPINION:

The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.

812

项与利拉鲁肽相关的新闻（医药）

2024-04-26

·生物谷

GLP-1RA治疗T2DM患者具有明确的心血管获益，与其抗动脉粥样硬化密不可分！

截止至目前为止，糖尿病仍然是全球范围内的重大疾病之一，根据国际糖尿病联盟（IDF）的数据，2019年全球糖尿病患病率估计为9.3%，约有4.63亿人患有糖尿病。截止至目前为止，糖尿病仍然是全球范围内的重大疾病之一，根据国际糖尿病联盟（IDF）的数据，2019年全球糖尿病患病率估计为9.3%，约有4.63亿人患有糖尿病，到2030年，糖尿病的全球预计患病率将增加到10.2%（5.78亿），到2045年将增加到10.9%（7亿）[1]。除了具有发病率高的特点外，糖尿病还是全球范围内死亡和残疾的主要原因，其中心血管并发症占据着重要因素，约占26.8%[2]。在确定排除了传统心血管疾病的危险因素后，包括年龄、肥胖、吸烟、血脂异常和高血压等，糖尿病患者发生心血管不良事件的几率明显高于非糖尿病患者。糖尿病并发的心血管不良事件，不仅给患者的生活质量和生命健康造成了严重威胁，同时也给全球范围内的患者和医疗保健系统带来了巨大的经济负担，具有严重的危害性。因此，全面和深入了解糖尿病的心血管不良事件风险，以确定早期预防和干预的策略，对于保障糖尿病患者生命健康安全具有重要的意义。近年来，由于对糖尿病不良并发症认识的加深和各类新型药物的研发、验证和应用，糖尿病患者的心血管风险呈现出一定的下降趋势。冠心病又称为动脉粥样硬化性心脏病，是心血管不良并发症的主要类型，可表现为稳定性心绞痛、不稳定性心绞痛、心肌梗死和心源性猝死。动脉粥样硬化及其危险因素均促进多种心血管事件的发生，并导致死亡[3]（见表1）。在全球范围内有高达32.2%的2型糖尿病（T2DM）患者可并发冠心病[4]。因此，如何应对动脉粥样硬化性心脏病是近年来糖尿病治疗的重点和热点问题。图1.动脉粥样硬化在心血管事件链中的作用糖尿病相关的心血管不良事件等并发症，给糖尿病的管理策略带来了严峻的挑战，但同时，多项有关评估糖尿病治疗药物的心血管结局试验（CVOT）正在进行或已经完成，为新阶段的糖尿病防治心血管疾病治疗提供了全新的见解和应对方案。肠促胰素，包括胰高血糖素样肽-1（GLP-1）和葡萄糖依赖性胰岛素性多肽（GIP），均属于肠道激素，在营养摄入时分泌，并通过调节胰岛素和胰高血糖素释放来维持血糖控制。GLP-1受体激动剂（GLP-1RA）可通过刺激肠源性肠促胰素的作用或抑制其降解来改善葡萄糖调节，从而起到控制糖尿病患者血糖的作用。此外，根据美国食品和药物管理局的指导意见，新的降糖药物要确保心血管安全性，以应对糖尿病相关的心血管事件并发症的挑战。CVOT研究中主要以心血管死亡、非致死性心肌梗死和非致死性卒中为不良心血管终点（MACE），对GLP-1RA等糖尿病治疗药物的MACE进行了全面的评估。最新的荟萃分析显示，对于合并心脑血管疾病或心脑血管高危因素的T2DM患者，GLP-1RA药物可使其MACE获益，在T2DM患者中，GLP-1RA类药物对心血管病的二级预防与一级预防有效性一致[5]（见图2）。图2. 荟萃分析显示GLP-1RA可使T2DM患者MACE获益 LEADER研究表明，在心血管高危的T2DM患者中，利拉鲁肽较安慰剂显示出显著的心血管获益[6]。来自LEADER研究的另一项分析显示利拉鲁肽还具有降低T2DM合并心血管高危患者的心肌梗死发生率，并可能改善患者心肌梗死的临床结局[7]。CVOT荟萃分析提示，GLP-1RA总体降低MACE风险达14%，其中利拉鲁肽降低MACE风险13%，司美格鲁肽降低MACE风险达26%[8]。大量研究证实GLP-1在人体内具有多重重要的生理作用，GLP-1RA通过激活GLP-1受体以葡萄糖浓度依赖性刺激胰岛素分泌、诱导β细胞增殖及增强对细胞凋亡的抵抗力，还通过直接作用于脂肪组织来促进能量储存，并通过刺激成骨细胞增殖和抑制细胞凋亡来增强骨形成，并可通过调控血压、炎症、血脂异常和微血管功能等动脉粥样硬化的危险因素来达到减少心血管并发症的目的[9]（见表3）。图3.GLP-1改善多种动脉粥样硬化的危险因素动脉粥样硬化的形成和进展是一个复杂的过程，在血管内皮受损的基础上，循环中的低密度脂蛋白（LDL）颗粒从血管腔被运输到血管壁，在细胞外基质中聚积，从而更容易发生氧化，巨噬细胞和平滑肌细胞吞噬脂质后形成泡沫细胞，促进动脉粥样硬化斑块的形成。GLP-1RA可通过减少极低密度脂蛋白、体内泡沫细胞、体内巨噬细胞、内皮功能障碍和氧化应激等多种途径抑制动脉粥样硬化的发生和发展[10]（见图4）。图4.GLP-1RA抑制动脉粥样硬化的多种机制一项动物研究显示，司美格鲁肽和利拉鲁肽等GLP-1RA显著减轻了载脂蛋白E（ApoE）缺陷小鼠和低密度脂蛋白受体缺陷（LDLr）小鼠的斑块病变发展。GLP-1RA可能通过作用于白细胞募集、白细胞滚动、粘附/外渗、胆固醇代谢、脂质介导的信号传导、细胞外基质蛋白转换等多种途径和其抗炎机制来抑制动脉粥样硬化斑块的形成[11]（见图5）。图5.GLP-1RA减少高脂饮食诱导的动脉粥样硬化斑块形成另一项动物研究显示，使用腺病毒载体系统转染ApoE-/-小鼠模型，并给予西方饮食喂养诱导动脉粥样硬化，取小鼠主动脉根部和主动脉弓进行油红染色（Oil-red-O）及天狼猩红染色（PSR）染色观察。结果显示，GLP-1(7-37)、GLP-1(9-37)和GLP-1(28-37)可显著减少小鼠动脉粥样硬化脂质核心并增加纤维帽厚度，达到稳定斑块作用[12]（见图6）。图6.GLP-1RA减少动脉粥样硬化斑块脂质核心及增加纤维帽厚度（稳定斑块）糖尿病相关心血管不良事件仍是糖尿病管理中面临的重大挑战，我们仍需重视心血管并发症的危害。GLP-1RA相关的CVOT试验和其他新进展均证实了包括利拉鲁肽和司美格鲁肽在内的GLP-1RA药物在降糖可靠的基础上，具有显著的抑制动脉粥样硬化进展的作用，并可进一步降低心血管不良事件，这对提高患者生活质量和降低死亡等不良结局均具有十分重要的价值。 [1]Saeedi P , Petersohn I, Salpea P , et al. Global and regional diabetes prev-alence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. [2]Ling W , Huang Y , Huang YM, et al. Global trend of diabetes mortality attributed to vascular complications, 2000–2016. Cardiovasc Diabetol. 2020;19:182 [3]Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850-2870. [4] Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83. [5]Sattar N et al. Lancet Diabetes Endocrinol. 2021; S2213-8587(21)00203-5. [6]Verma S, Poulter NR, Bhatt DL, et al. Effects of liraglutide oncardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation 2018;138:2884–2894 [7]Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB: Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). Am J Cardiol. 2018; 121(12):1467-1470. [8]Sattar N, Lee MMY,Kristensen SL,et al.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.Lancet Diabetes Endocrinol. 2021;9(10):653-662. [9]Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850-2870. [10]Rizzo M, Nikolic D, Patti AM, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9 Pt B):2814-2821. [11]Rakipovski G, Rolin B, Nøhr J, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3(6):844-857. Published 2018 Nov 21. [12]Burgmaier M, Liberman A, Möllmann J, et al. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice. Atherosclerosis. 2013;231(2):427-435. 作者简介：程时武教授解放军第923医院内分泌科主任，副主任医师，医学博士毕业于第四军医大学、解放军301医院广西医师协会内分泌代谢科医师分会副主任委员广西医学会内分泌学分会常委广西医学会糖尿病学分会委员

临床结果申请上市优先审批

2024-04-24

·PRNewswire

NABP Report Explores How Illegal Online Sellers Exploit Consumer Demand for Weight Loss Drugs

MOUNT PROSPECT, Ill., April 24, 2024 /PRNewswire/ -- The National Association of Boards of Pharmacy® (NABP®) released a new RogueRx Activity Report, Injectable Weight Loss Drugs: How Illegal Online Drug Sellers Are Taking Advantage of Patients, which explores how bad actors are taking advantage of glucagon-like peptide-1 receptor agonist (GLP-1 agonist) medications "going viral." This class of drugs, including semaglutide, liraglutide, and tirzepatide, is used to treat type 2 diabetes and obesity. Among patients, these drugs are commonly known for promoting weight loss. Unfortunately, because of the drugs' popularity, criminals have seized the opportunity to illegally sell the drugs online, putting patients at risk. Continue Reading These GLP-1 agonists are in high demand by patients; however, they are expensive and often not covered by insurance. In addition, some dosages of these approved drugs are on Food and Drug Administration's Drug Shortage List, meaning that the available supply cannot meet the current demand. As a result, some patients go online to find these popular medications. Illegal online sellers are exploiting this demand by offering substandard and falsified GLP-1 agonists to vulnerable patients. According to the Partnership for Safe Medicines, substandard and falsified Ozempic® has been found in at least 16 countries to date. In the report, NABP highlights the methods illegal actors use to sell substandard or falsified GLP-1 agonists: NABP's RogueRx Activity Report explores illegal activity that has followed the rise of injectable weight loss drugs. Post this Criminals sell these drugs online without requiring a valid prescription and without the required pharmacy licenses. Some bad actors trick purchasers by mimicking legal sellers' websites, branding, or packaging. Others employ a non-delivery scheme, meaning patients never receive the goods they pay for online. Sellers may also try to skirt enforcement by advertising drugs as "peptides" with claims that they are for "research purposes only" and "not for human consumption." Government agencies around the world are actively investigating illegal sellers, and online marketplaces and e-advertising platforms are working to remove illegal drug sellers from their platforms. NABP applauds the efforts of these agencies and organizations. Patients are encouraged to visit NABP's Safe Pharmacy website for resources, such as the Safe Site Search Tool, to help protect them when purchasing medication online. Learn how you can warn patients against illegal online sellers of GLP-1 agonists by reading the RogueRx Activity Report. About NABP NABP is the independent, international, and impartial 501(c)(3) nonprofit Association that assists its state member boards and jurisdictions in protecting the public health. NABP was established in 1904 to assist the state boards of pharmacy in creating uniform education and licensure standards. Today, we help support patient and prescription drug safety through examinations that assess pharmacist competency, pharmacist licensure transfer and verification services, and various pharmacy accreditation and inspection programs. Media Contact: [email protected] SOURCE National Association of Boards of Pharmacy

2024-04-23

·药智网

全球管线数量TOP25医药公司，中国占了4席

近日，全球知名的药品、医疗器械、医药公司、临床试验及市场智库Citeline发布了《2024年医药研发年度回顾》（所有数据收集截至2024年1月2日）。报告显示，2023年全球研发管线规模再创新高，且增速再次上升。截至2024年1月2日，全球共有22825种药物正在开发，同比增长7.20%，超过过去五年的平均增速（7.14%）。从研发活动看，涉及中国的药物研发比例上升3.1%至26.7%，成为仅次于美国的全球第二大规模体。报告中，Citeline评选出了全球管线数量TOP25的制药公司，其中有4家中国公司入选，并且有一家中国公司进入全球Top10。今年上榜企业中，排名前10位的依次是：罗氏、辉瑞、阿斯利康、礼来、百时美施贵宝、诺华、强生、恒瑞医药、默沙东、赛诺菲。01第8位：恒瑞医药中国医药企业恒瑞医药今年首次跻身全球TOP10，2022年恒瑞医药首次进入该榜单，排名第16位，2023年排名上升至第13位。《2024年医药研发年度回顾》称，在TOP25药企中，管线规模增长最明显的也是恒瑞医药。目前恒瑞医药已在国内获批上市16款1类创新药、4款2类新药，同时临床研发也加速推进。2023年，恒瑞医药有12项临床推进至Ⅲ期，35项临床推进至Ⅱ期，30项临床推进至Ⅰ期，公司有90多个自主创新产品正在临床开发，近300项临床试验在国内外开展。近十年以来，恒瑞医药累计研发投入超300亿元，位居全国医药行业前列。公司还在连云港、上海、美国和欧洲等地设立14个研发中心，全球研发团队达5000余人。2023年恒瑞医药国际化取得重大突破，共达成了总交易金额超40亿美元的5项授权合作。其中，恒瑞医药将抗癌创新药HRS-1167与SHR-A1904独家许可给德国默克，交易总金额可超14亿欧元，这也是恒瑞首次与全球大型跨国药企合作。02第15位：中国生物制药中国生物制药从研发管线规模上成为中国第二大药企，跻身全球第15位，管线规模较上年大幅增长72%，新增至103个。2023年，中国生物制药研发投入金额达44亿元，占总收入比例的16.8%，有6个创新药及生物类似药获批，创新产品数量由2015年的2个，快速攀升至2023年的11个。随着创新版图的不断扩大，创新产品已成为公司收入增长的重要动力。2023年，公司创新产品收入达到98.9亿元，同比增加13.3%。创新收入占总收入比例从2015年的11%，迅速提升至2023年的38%。未来三年，中国生物制药将迎来全面创新战略下的密集收获期，仅2024年，贝莫苏拜单抗（TQB2450）、ALK抑制剂依奉阿克（TQB3139）、ROS1抑制剂安奈克替尼（TQB3101）、利拉鲁肽等多个创新产品预计获批上市。03第17位：复星医药国内药企中，排名第3的是复兴医药，全球排名第17位。2023年，复星医药研发投入共计人民币59.37亿元，同比增加0.88%；其中，研发费用为人民币43.46亿元，同比增加1.02%。制药业务研发投入人民币51.72亿元，同比增长1.47%。复星医药主要在研创新药、生物类似药项目超过70项（按适应症计算），未来公司将重点布局小分子、抗体/ADC、RNA和细胞疗法四大核心技术平台，并积极探索肿瘤疫苗、AI药物研发等前沿技术的布局。04第24位：石药集团石药集团连续第二年进入全球管线规模TOP25，位列第24，也是国内药企的第4位。2023年研发费用达人民币48.3亿元（计入收益表中），同比增加21.2%，约占成药业务收入18.8%。目前，石药集团有超过60个重点在研药物已进入临床或申报阶段，其中7个已递交上市申请，18个处于注册临床阶段。2023年，石药集团与Corbus Pharmaceuticals,Inc.签订独家授权协议，向其售出公司开发的抗体药物偶联物SYS6002在美国、欧盟、英国等地的开发及商业化权利。石药集团收取750万美元的首付款，并有权收取最多1.3亿美元的潜在开发及监管里程碑付款以及最多5.55亿美元的潜在销售里程碑付款。来源 | 医药投资部落（药智网获取授权转载）责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

临床3期财报生物类似药临床1期上市批准

100 项与利拉鲁肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	利拉鲁肽	A10BJ02	DB06655

研发状态

适应症	最高研发状态	国家/地区	公司
2型糖尿病	批准上市	中国更多	Novo Nordisk A/S 更多
超重	批准上市	美国更多	Novo Nordisk, Inc. 更多
肥胖	批准上市	冰岛更多	Novo Nordisk A/S 更多
糖尿病	无进展	西班牙更多	Novo Nordisk A/S 更多
普拉德-威利综合症	无进展	加拿大更多	Novo Nordisk A/S 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03158805 (CTgov)	临床2期	肥胖 \| 躁郁症	60	liraglutide (Active Drug)	鹽選鏇餘鹽艱廠鬱憲餘(鹽顧齋構鑰網製鹽網蓋) = 選遞遞鹹製醖鏇壓積範構鏇糧獵糧簾願膚壓選 (製憲淵餘願窪糧鑰蓋餘, 築夢範觸鑰憲齋願遞鑰 ~ 醖憲願鬱餘齋鏇衊憲鏇) 更多	-	2024-03-27
				Placebo (Placebo)	鹽選鏇餘鹽艱廠鬱憲餘(鹽顧齋構鑰網製鹽網蓋) = 網淵鬱選築鬱襯夢齋壓構鏇糧獵糧簾願膚壓選 (製憲淵餘願窪糧鑰蓋餘, 膚壓構積範夢壓淵淵醖 ~ 鏇齋網憲鏇衊鑰範鑰鹽) 更多
NCT02953665 (CTgov)	临床2期	帕金森病	63	Liraglutide (Liraglutide)	鹽製壓衊壓膚遞獵鬱廠(網觸襯夢顧簾衊壓憲鏇) = 築夢艱遞壓蓋願淵鹹窪繭範鏇鏇積網鬱觸襯願 (簾壓鬱網淵築獵餘選鹹, 襯繭網蓋餘艱製觸鹽積 ~ 衊蓋窪餘衊窪範齋夢壓) 更多	-	2024-03-07
				Placebo (Placebo)	鹽製壓衊壓膚遞獵鬱廠(網觸襯夢顧簾衊壓憲鏇) = 築鹹餘壓獵觸齋遞選鬱繭範鏇鏇積網鬱觸襯願 (簾壓鬱網淵築獵餘選鹹, 鑰鑰鏇襯夢範糧鬱遞鬱 ~ 衊夢觸觸夢築鑰願壓夢) 更多
NCT02777073 (CTgov)	N/A	高血糖 \| 1型糖尿病	43	Victoza (Liraglutide 1.8 mg)	選鑰製齋鏇鹽膚夢艱鬱(鏇廠製簾衊遞構糧鏇願) = 積積鏇憲襯範獵觸蓋獵憲廠鹹憲網獵獵醖觸鏇 (蓋艱衊淵壓鹹遞鑰築觸, 製繭廠鹹衊觸憲膚顧蓋 ~ 窪窪鬱鹹選膚糧憲壓願) 更多	-	2024-02-29
				Placebo (Placebo)	選鑰製齋鏇鹽膚夢艱鬱(鏇廠製簾衊遞構糧鏇願) = 顧鬱鹽獵網襯壓膚窪範憲廠鹹憲網獵獵醖觸鏇 (蓋艱衊淵壓鹹遞鑰築觸, 壓觸蓋遞餘餘鏇餘膚選 ~ 憲壓壓積鬱選積遞願顧) 更多
NCT02518945 (CTgov)	临床3期	1型糖尿病	26	Insulin+Liraglutide (Placebo)	鹽獵鏇夢積選壓鹹網糧(淵簾願鏇窪繭廠簾憲鏇) = 壓願廠鹹廠簾襯夢鑰艱蓋艱艱顧鑰艱製顧製製 (艱築餘觸遞鹽鑰選餘積, 積淵網觸構網鹹糧糧觸 ~ 窪憲獵築齋簾糧鹹遞製) 更多	-	2024-01-24
				Insulin+Liraglutide+Dapagliflozin (Active Drugs)	鹽獵鏇夢積選壓鹹網糧(淵簾願鏇窪繭廠簾憲鏇) = 夢鏇選艱窪窪淵築廠鏇蓋艱艱顧鑰艱製顧製製 (艱築餘觸遞鹽鑰選餘積, 獵觸積遞壓窪觸憲廠夢 ~ 觸顧築艱夢衊淵齋獵餘) 更多
NCT01722240 (CTgov)	临床3期	1型糖尿病	69	Placebo	簾鹽餘衊簾網蓋艱積製(獵獵醖醖鹽構艱醖網膚) = 製簾餘鏇鏇鬱願積遞鏇壓遞壓鏇觸鑰艱築繭製 (範窪築襯願鹽範觸觸蓋, 顧鏇襯簾淵廠鏇網餘積 ~ 鹽齋夢壓夢繭範選糧選) 更多	-	2024-01-23
NCT03158805 (Pubmed)	临床2期	-	60	Liraglutide 3.0 mg/d	獵鏇構網鑰鹽餘壓獵顧(選淵築顧壓餘壓廠鏇繭) = 鑰窪夢糧鑰夢齋鑰鹹蓋餘遞鹽構齋窪顧鏇窪襯 (淵廠網鹹衊衊壓鏇製壓 )	-	2024-01-16
ESPE2023	N/A	2型糖尿病 \| 肥胖	22	Liraglutide	齋構淵衊觸衊蓋齋醖製(鹽鏇範餘構衊壓鑰網範) = 艱構蓋構襯鏇襯範齋簾憲廠製膚壓簾窪鬱顧醖 (淵糧鬱鏇淵繭鬱鹽鏇鹹 ) 更多	不佳	2023-09-21
ESPE2023	N/A	肥胖	9	Liraglutide	壓衊選艱製鬱選餘積製(膚夢範範憲糧鑰糧壓顧) = 範網淵範鏇築網窪遞餘願選艱艱觸網鏇願繭築 (窪鑰壓齋淵窪繭窪積積 ) 更多	积极	2023-09-21
ESPE2023	N/A	普拉德-威利综合症	-	GLP-1 analog	獵觸鑰築網獵糧憲窪築(遞糧積醖膚膚糧衊製顧) = 積範繭願衊夢鑰糧窪網夢憲遞窪鑰廠衊鹽夢鹹 (獵糧衊構範鏇網鬱遞製, 4.96) 更多	积极	2023-09-21
				GLP-1 analog (Liraglutide)	獵觸鑰築網獵糧憲窪築(遞糧積醖膚膚糧衊製顧) = 願糧顧淵憲網範鬱窪鏇夢憲遞窪鑰廠衊鹽夢鹹 (獵糧衊構範鏇網鬱遞製, 4.75) 更多
ESPE2023	N/A	病态肥胖 proximal microdeletion syndrome 16p11.2	13	Liraglutide	衊網鑰鏇夢獵鹹壓鏇艱(積憲窪積蓋醖繭餘糧糧) = 積範襯網範蓋範淵蓋網願製顧齋艱膚蓋選淵鹽 (鹽艱憲衊餘簾艱廠壓艱, 3.1) 更多	积极	2023-09-21